Mary A Venneri

List of Publications by Year
in descending order

59 papers	5,665 citations	201674 27 h-index	155660 55 g-index
60 all docs	60 docs citations	60 times ranked	7665 citing authors

#	Article	IF	Citations
1	Angiogenic factors as prognostic markers in neuroendocrine neoplasms. Endocrine, 2022, , 1.	2.3	10
2	Human genital tracts microbiota: dysbiosis crucial for infertility. Journal of Endocrinological Investigation, 2022, 45, 1151-1160.	3.3	26
3	The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males. Autophagy, 2022, 18, 1662-1672.	9.1	25
4	MicroRNA loaded edible nanoparticles: an emerging personalized therapeutic approach for the treatment of obesity and metabolic disorders. Theranostics, 2022, 12, 2631-2634.	10.0	5
5	Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Science Translational Medicine, 2022, 14, .	12.4	24
6	Cortisol Circadian Rhythm and Insulin Resistance in Muscle: Effect of Dosing and Timing of Hydrocortisone Exposure on Insulin Sensitivity in Synchronized Muscle Cells. Neuroendocrinology, 2021, 111, 1005-1028.	2.5	9
7	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 511-525.	5.7	13
8	Targeting the NOâ€cGMPâ€PDE5 pathway in COVIDâ€19 infection. The DEDALO project. Andrology, 2021, 9, 33-38.	3.5	47
9	Diabetic Cardiomiopathy Progression is Triggered by miR122-5p and Involves Extracellular Matrix. JACC: Cardiovascular Imaging, 2021, 14, 1130-1142.	5.3	29
10	Impaired Immune Function in Patients With Chronic Postsurgical Hypoparathyroidism: Results of the EMPATHY Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2215-e2227.	3.6	16
11	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine, 2021, 65, 103246.	6.1	52
12	Novel Nanoarchitectures Based on Lignin Nanoparticles for Electrochemical Eco-Friendly Biosensing Development. Nanomaterials, 2021, 11, 718.	4.1	9
13	Gold Nanoparticles/Carbon Nanotubes and Gold Nanoporous as Novel Electrochemical Platforms for L-Ascorbic Acid Detection: Comparative Performance and Application. Chemosensors, 2021, 9, 229.	3.6	7
14	Calcineurin Gamma Catalytic Subunit PPP3CC Inhibition by miR-200c-3p Affects Apoptosis in Epithelial Ovarian Cancer. Genes, 2021, 12, 1400.	2.4	4
15	Priming metabolism with the type 5 phosphodiesterase: the role of cGMP-hydrolyzing enzymes. Current Opinion in Pharmacology, 2021, 60, 298-305.	3.5	8
16	Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study. Cancers, 2021, 13, 6355.	3.7	18
17	Thyroid disorders in programmed death 1 inhibitorâ€treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?. Clinical Endocrinology, 2020, 92, 258-265.	2.4	18
18	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. Endocrines, 2020, 1, 90-101.	1.0	3

#	Article	IF	Citations
19	The Immune System in Cushingâ€™s Syndrome. Trends in Endocrinology and Metabolism, 2020, 31, 655-669.	7.1	79
20	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine, 2020, 69, 441-450.	2.3	26
21	Disruption of Circadian Rhythms: A Crucial Factor in the Etiology of Infertility. International Journal of Molecular Sciences, 2020, 21, 3943.	4.1	59
22	Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?. Trends in Endocrinology and Metabolism, 2020, 31, 631-641.	7.1	22
23	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. Journal of Endocrinological Investigation, 2020, 43, 1141-1147.	3.3	103
24	Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy. Journal of Endocrinology, 2020, 246, R13-R31.	2.6	37
25	PDE5 Inhibition Stimulates Tie2-Expressing Monocytes and Angiopoietin-1 Restoring Angiogenic Homeostasis in Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2623-2636.	3.6	21
26	The Sex-Specific Detrimental Effect of Diabetes and Gender-Related Factors on Pre-admission Medication Adherence Among Patients Hospitalized for Ischemic Heart Disease: Insights From EVA Study. Frontiers in Endocrinology, 2019, 10, 107.	3.5	6
27	Non-AÎ²-Dependent Factors Associated with Global Cognitive and Physical Function in Alzheimerâ€™s Disease: A Pilot Multivariate Analysis. Journal of Clinical Medicine, 2019, 8, 224.	2.4	6
28	Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. European Journal of Endocrinology, 2018, 178, 501-511.	3.7	56
29	Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 173-185.	11.4	155
30	Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 270-271.	11.4	1
31	USPIOâ€labeling in M1 and M2â€polarized macrophages: An in vitro study using a clinical magnetic resonance scanner. Journal of Cellular Physiology, 2018, 233, 5823-5828.	4.1	9
32	Chronic phosphodiesterase type 5 inhibition has beneficial effects on subcutaneous adipose tissue plasticity in type 2 diabetic mice. Journal of Cellular Physiology, 2018, 233, 8411-8417.	4.1	9
33	Circadian Rhythm of Glucocorticoid Administration Entrains Clock Genes in Immune Cells: A DREAM Trial Ancillary Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2998-3009.	3.6	55
34	Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?. Frontiers in Endocrinology, 2018, 9, 434.	3.5	14
35	Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Scientific Reports, 2017, 7, 44584.	3.3	33
36	PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1525-1534.	3.6	48

#	Article	IF	Citations
37	Activated c-Kit receptor in the heart promotes cardiac repair and regeneration after injury. Cell Death and Disease, 2016, 7, e2317-e2317.	6.3	38
38	Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes. Journal of Endocrinological Investigation, 2016, 39, 1235-1246.	3.3	58
39	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never) Tj ETQq1 1 0.784314 rgBT /Over	3.3	26
40	Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic Mice. PLoS ONE, 2015, 10, e0126580.	2.5	45
41	Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. Expert Opinion on Therapeutic Targets, 2015, 19, 1617-1622.	3.4	39
42	Hematopoietic Stem/Progenitor Cells: Response to Chemotherapy. , 2012, , 333-344.		2
43	Proangiogenic Tie2+ Macrophages Infiltrate Human and Murine Endometriotic Lesions and Dictate Their Growth in a Mouse Model of the Disease. American Journal of Pathology, 2011, 179, 2651-2659.	3.8	96
44	Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene, 2011, 30, 4231-4242.	5.9	221
45	The Notch2â€“Jagged1 interaction mediates stem cell factor signaling in erythropoiesis. Cell Death and Differentiation, 2011, 18, 371-380.	11.2	23
46	Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 741-749.	2.4	105
47	A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood â€œresidentâ€•monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood, 2009, 114, 901-914.	1.4	306
48	Tumor-Targeted Interferon-Î± Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. Cancer Cell, 2008, 14, 299-311.	16.8	267
49	Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood, 2007, 109, 5276-5285.	1.4	451
50	Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends in Immunology, 2007, 28, 519-524.	6.8	255
51	Safety of Arylsulfatase A Overexpression for Gene Therapy of Metachromatic Leukodystrophy. Human Gene Therapy, 2007, 18, 821-836.	2.7	47
52	Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nature Medicine, 2006, 12, 585-591.	30.7	460
53	57. Targeted Gene Delivery of Alpha-Interferon by Genetically Modified Hematopoietic Cells Inhibits Glioma Vascularization and Growth without Systemic Toxicity. Molecular Therapy, 2006, 13, S24.	8.2	0
54	803. Endogenous microRNA Regulation Suppresses Transgene Expression in Hematopoietic Lineages and Enables Stable Gene Transfer. Molecular Therapy, 2006, 13, S311.	8.2	0

#	Article	IF	Citations
55	Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nature Biotechnology, 2005, 23, 108-116.	17.5	293
56	Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell, 2005, 8, 211-226.	16.8	1,212
57	Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nature Medicine, 2003, 9, 789-795.	30.7	539
58	In VivoTargeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors. Human Gene Therapy, 2003, 14, 1193-1206.	2.7	114
59	Sex-Specific Effects of Daily Tadalafil on Contraction Kinetics of the Diabetic Heart. The RECOGITO Randomized, Double-Blind, Placebo-Controlled Trial. SSRN Electronic Journal, 0, , .	0.4	0